Study of Ketamine as an Antidepressant in Major Depressive Disorder

Phase 1/2 Unknown 35 enrolled Shi Jinyun

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Outcome Measures: Evaluate the changes in neuroimaging and biochemistry measures with ketamine treatment. Secondary Outcome Measures: Evaluate the effects of ketamine on depression symptoms, manic symptoms, global change in psychiatric symptoms, and suicidal ideation.

Timeline

Start: 2012-02
Primary completion: 2012-12
Completion: 2013-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	0.5 mg/kg	—

Study of Ketamine as an Antidepressant in Major Depressive Disorder

Summary

Timeline

Drugs

Indications